Ablynx NV - Strategic SWOT Analysis Review

Ablynx NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Ablynx NV (Ablynx), a subsidiary of Sanofi is a biopharmaceutical company that focuses on developing Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. The company has a portfolio of Nanobody-based therapeutic programs in various major disease areas, including inflammation, haematology, immuno-oncology and oncology. The company’s proprietary Nanobody platform allows the rapid generation and large-scale production of novel biological therapeutics that have potential to be used in a wide range of human diseases. The company has research collaborations and significant partnerships with key pharmaceutical companies including Merck, Boehringer Ingelheim and Novartis. Ablynx is headquartered in Ghent, Belgium.

Ablynx NV Key Recent Developments

Feb 22,2018: ABLYNX ANNOUNCES 2017 FULL YEAR RESULTS
Feb 07,2018: Ablynx Announces Resignation of Dr Bo Jesper Hansen From the Board of Directors
Jan 24,2018: Ablynx Names Dr Robert Friesen as Chief Scientific Officer
Jan 08,2018: Ablynx Announces Board Changes

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.